Cargando…
Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study)
INTRODUCTION: A substantial proportion of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), report persisting symptoms weeks and months following acute infection. Estimates on prevalence vary due to differences in study designs, populations, heterogeneity of sym...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251892/ https://www.ncbi.nlm.nih.gov/pubmed/35777877 http://dx.doi.org/10.1136/bmjopen-2022-062439 |
_version_ | 1784740133182898176 |
---|---|
author | Mutubuki, Elizabeth N van der Maaden, Tessa Leung, Ka Yin Wong, Albert Tulen, Anna D de Bruijn, Siméon Haverman, Lotte Knoop, Hans Franz, Eelco van Hoek, Albert Jan van den Wijngaard, Cees C |
author_facet | Mutubuki, Elizabeth N van der Maaden, Tessa Leung, Ka Yin Wong, Albert Tulen, Anna D de Bruijn, Siméon Haverman, Lotte Knoop, Hans Franz, Eelco van Hoek, Albert Jan van den Wijngaard, Cees C |
author_sort | Mutubuki, Elizabeth N |
collection | PubMed |
description | INTRODUCTION: A substantial proportion of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), report persisting symptoms weeks and months following acute infection. Estimates on prevalence vary due to differences in study designs, populations, heterogeneity of symptoms and the way symptoms are measured. Common symptoms include fatigue, cognitive impairment and dyspnoea. However, knowledge regarding the nature and risk factors for developing persisting symptoms is still limited. Hence, in this study, we aim to determine the prevalence, severity, risk factors and impact on quality of life of persisting symptoms in the first year following acute SARS-CoV-2 infection. METHODS AND ANALYSIS: The LongCOVID-study is both a prospective and retrospective cohort study being conducted in the Netherlands, with a one year follow-up. Participants aged 5 years and above, with self-reported positive or negative tests for SARS-CoV-2 will be included in the study. The primary outcome is the prevalence and severity of persistent symptoms in participants that tested positive for SARS-CoV-2 compared with controls. Symptom severity will be assessed for fatigue (Checklist Individual Strength (CIS subscale fatigue severity)), pain (Rand-36/SF-36 subscale bodily pain), dyspnoea (Medical Research Council (mMRC)) and cognitive impairment (Cognitive Failure Questionnaire (CFQ)). Secondary outcomes include effect of vaccination prior to infection on persistent symptoms, loss of health-related quality of life (HRQoL) and risk factors for persisting symptoms following infection with SARS-CoV-2. ETHICS AND DISSEMINATION: The Utrecht Medical Ethics Committee (METC) declared in February 2021 that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study (METC protocol number 21-124/C). Informed consent is required prior to participation in the study. Results of this study will be submitted for publication in a peer-reviewed journal. |
format | Online Article Text |
id | pubmed-9251892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-92518922022-07-05 Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) Mutubuki, Elizabeth N van der Maaden, Tessa Leung, Ka Yin Wong, Albert Tulen, Anna D de Bruijn, Siméon Haverman, Lotte Knoop, Hans Franz, Eelco van Hoek, Albert Jan van den Wijngaard, Cees C BMJ Open Infectious Diseases INTRODUCTION: A substantial proportion of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), report persisting symptoms weeks and months following acute infection. Estimates on prevalence vary due to differences in study designs, populations, heterogeneity of symptoms and the way symptoms are measured. Common symptoms include fatigue, cognitive impairment and dyspnoea. However, knowledge regarding the nature and risk factors for developing persisting symptoms is still limited. Hence, in this study, we aim to determine the prevalence, severity, risk factors and impact on quality of life of persisting symptoms in the first year following acute SARS-CoV-2 infection. METHODS AND ANALYSIS: The LongCOVID-study is both a prospective and retrospective cohort study being conducted in the Netherlands, with a one year follow-up. Participants aged 5 years and above, with self-reported positive or negative tests for SARS-CoV-2 will be included in the study. The primary outcome is the prevalence and severity of persistent symptoms in participants that tested positive for SARS-CoV-2 compared with controls. Symptom severity will be assessed for fatigue (Checklist Individual Strength (CIS subscale fatigue severity)), pain (Rand-36/SF-36 subscale bodily pain), dyspnoea (Medical Research Council (mMRC)) and cognitive impairment (Cognitive Failure Questionnaire (CFQ)). Secondary outcomes include effect of vaccination prior to infection on persistent symptoms, loss of health-related quality of life (HRQoL) and risk factors for persisting symptoms following infection with SARS-CoV-2. ETHICS AND DISSEMINATION: The Utrecht Medical Ethics Committee (METC) declared in February 2021 that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study (METC protocol number 21-124/C). Informed consent is required prior to participation in the study. Results of this study will be submitted for publication in a peer-reviewed journal. BMJ Publishing Group 2022-07-01 /pmc/articles/PMC9251892/ /pubmed/35777877 http://dx.doi.org/10.1136/bmjopen-2022-062439 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Infectious Diseases Mutubuki, Elizabeth N van der Maaden, Tessa Leung, Ka Yin Wong, Albert Tulen, Anna D de Bruijn, Siméon Haverman, Lotte Knoop, Hans Franz, Eelco van Hoek, Albert Jan van den Wijngaard, Cees C Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
title | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
title_full | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
title_fullStr | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
title_full_unstemmed | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
title_short | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
title_sort | prevalence and determinants of persistent symptoms after infection with sars-cov-2: protocol for an observational cohort study (longcovid-study) |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251892/ https://www.ncbi.nlm.nih.gov/pubmed/35777877 http://dx.doi.org/10.1136/bmjopen-2022-062439 |
work_keys_str_mv | AT mutubukielizabethn prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT vandermaadentessa prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT leungkayin prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT wongalbert prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT tulenannad prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT debruijnsimeon prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT havermanlotte prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT knoophans prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT franzeelco prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT vanhoekalbertjan prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT vandenwijngaardceesc prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy |